NCT00111657View on ClinicalTrials.gov

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Gout

Interventions

BIOLOGICAL

Pegloticase

8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

Savient Pharmaceuticals

All Listed Sponsors

collaborator

Savient Pharmaceuticals

INDUSTRY

lead

John Sundy

OTHER